Aquanova to showcase ongoing research and new white label initiative at SupplySide Global

Aquanova NA Corp will be showcasing new clinical research and white label finished products offerings at this year’s SupplySide Global 2025. More specifically, Aquanova will highlight clinical validation for its NovaSOL Curcumin ingredient for mobility, and NovaSOL Q10 for energy. A randomized, placebo-controlled human trial is currently underway evaluating the combination of NovaSOL Curcumin, boswellia, and vitamin D3 for potential anti-inflammatory benefits, mobility, and endurance.

In the 60-day study 54 adults with elevated inflammatory markers will be assessed for changes in inflammatory markers such as IL-6, TNF-α, CRP, and ESR (primary endpoint), as well as functional mobility based on WOMAC scores, safety, and tolerability (secondary endpoints). The trial also directly compares NovaSOL formulations to native compounds, competing products, and placebo to validate the ingredient’s bioavailability advantages. Aquanova expects results in Q1 of 2026.

The company is also conducting an open-label, randomized, single-dose crossover trial to assess the bioavailability of the NovaSOL Q10 compared to native CoQ10 in 36 healthy adults. Researchers will measure pharmacokinetic parameters (Cmax, AUC) under fasting conditions over 72 hours. Primarily, the study will be evaluating absorption and exposure, with secondary endpoints monitoring safety and tolerability. Results are expected in Q4 2025.

In addition to research, Aquanova will be introducing its NovaSOL White Label initiative, offering a portfolio of ready-to-market dietary supplements incorporating the company’s micelle technology and clinically validated ingredients such as curcumin, astaxanthin, CoQ10, and Boswellia, in both softgel and liquid capsule formats.

“Our mission has always been to set the standard in bioavailability, ensuring that clinically relevant doses translate into meaningful outcomes,” said Frank Behnam, CEO, Aquanova, in a press release. “At SupplySide Global, we’re excited to showcase both the clinical evidence pipeline and practical product solutions that empower our partners to succeed.”

Aquanova’s research initiatives have been ongoing and fruitful. A recently published study found that the company’s NovaSOL Astaxanthin formulation improved skin health outcomes such as texture, luminosity, skin tone, hydration, smoothness, and redness. These results were based on both objective and subjective measures.

Additionally, its parent company, Aquanova AG, entered into a strategic agreement with Jupiter Neurosciences Inc. to jointly develop a series of consumer-facing nutritional products that target longevity, aging, and healthspan. Jupiter Neurosciences is a clinical-stage pharmaceutical company while Aquanova AG is a phyto-technology manufacturer that uses its NovaSol technology to deliver micellized ingredients. The two companies have collaborated for eight years, leading to the development of Jotrol, a proprietary resveratrol-based formulation that is advancing to a Phase IIa trial in Parkinson’s Disease.

This strategic partnership has led to the development of a line of longevity supplement called Nugevia, starting with three different formulas targeting mitochondrial function, beauty-from-within, and cognitive health. “Nugevia represents more than a product launch—it’s a strategic engine for growth,” stated Christer Rosén, chairman and CEO of Jupiter Neurosciences, in a June 9 press release. “By leveraging our core science in a consumer format, we’re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It’s smart capital allocation with real scientific impact.”

"We are incredibly proud of our partnership with Jupiter and look forward to the work they are doing to bring life-changing solutions for rare and difficult-to-treat diseases to market in the medicinal sphere and for superior supplement products targeting longevity and healthspan," said Frank Behnam, CEO of Aquanova, in a March 2025 statement. "Resveratrol is a powerful ingredient but it suffers from bioavailability and absorption challenges. Our NovaSol technology ensures that resveratrol safely reaches effective levels in the body, without GI-side effects, creating reliable health solutions in many indications.